Brand and Other Names:GoLytely, MiraLax, more...Glycolax, GoEvac, CoLav, CoLyte, NuLYTELY, polyethylene glycol electrolyte soln, polyethylene glycol powder, TriLyte
- Classes: Laxatives, Osmotic
Dosing & Uses
Dosage Forms & Strengths
Polyethylene glycol (PEG) content
powder for oral solution
17 g (~1 heaping tbsp) in 8 oz of clear liquid PO q10min until 2 L has been consumed or rectal effluent is clear
NG: 20-30 mL/min
17 g in 4-8 oz water PO once daily for ≤1 week
Refrigerate before administering to improve palatability
Have patient fast 3-4 hr before administering PEG
Encourage rapid drinking of each portion
MiraLax: Bottle top is measuring cup marked to contain 17 g
Advise patients to hydrate adequately before, during, and after use
Dosage Forms & Strengths
powder for oral solution
25-40 mL/kg/hr PO for 4-10 hr until rectal effluent is clear; total dose not to exceed 2 L
<6 months: Safety and efficacy not established
≥6 months: 0.5-1.5 g/kg PO once daily for no longer than 2 weeks; adjusted to effect; not to exceed 17 g/day
Frequency Not Defined
Colonic mucosal aphthous ulcerations
Osmotic laxative products may produce colonic mucosal aphthous ulcerations, including reports of more serious cases of ischemic colitis necessitating hospitalization
Avoid use in patients with bowel obstruction, megacolon, perforated bowel, ulcerative colitis, toxic colitis, gastric retention
Not indicated for children <2 years because of risk of hypoglycemia, dehydration, and hypokalemia
When using PEG as laxative, do not give for >1 week
Electrolyte imbalance reported with prolonged use
Risk of fluid and electrolyte abnormalities, arrhythmias, seizures, and renal impairment
Use with caution in renal insufficiency; ensure adequate hydration, and consider laboratory testing
Directly observe administration to patients at risk for aspiration
Products are not for direct ingestion but require dilution with water
Pregnancy & Lactation
Pregnancy category: C
Lactation: No data available
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Osmotic laxative; causes water retention in stool, causing increase in stool frequency
Onset: 24-96 hr
Excretion: Feces (93%), urine (0.2%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs